Caribou Biosciences shares rose after its CAR-T therapies showed high response rates and durable remissions in lymphoma and myeloma trials.
A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback